Sort by
Medicine and Dentistry
Adverse Event
33%
Age
16%
Albinterferon Alpha2b
50%
Alpha2a Interferon
50%
Arm
16%
Chronic Hepatitis
16%
Chronic Hepatitis C
33%
Fibrosis
16%
Gamma-Glutamyl Transpeptidase
16%
Genotype
33%
Group Therapy
16%
Hepacivirus
16%
Hepatitis C
33%
Hepatitis C Virus Genotype 2
33%
Hepatitis C Virus Genotype 3
16%
Human Albumin
16%
Human Interferon
16%
Intention-to-Treat Analysis
16%
Interferon Alfa 2b
16%
Patient
100%
Peginterferon
16%
Peginterferon Alpha
50%
Polypeptide
16%
Predictor
16%
Recommended Drug Dose
16%
Regression Analysis
16%
Ribavirin
16%
Steatosis
16%
Therapeutic Procedure
50%
Nursing and Health Professions
Adverse Event
33%
Alanine Aminotransferase Level
16%
Albinterferon Alpha2b
50%
Alpha2a Interferon
50%
Alpha2b Interferon
16%
Body Mass
16%
Chronic Hepatitis
16%
Chronic Hepatitis C
33%
Confidence Interval
50%
Fibrosis
16%
Gamma Glutamyltransferase
16%
Group Therapy
16%
Hepatitis C
33%
Human Albumin
16%
Human Interferon
16%
Inpatient
66%
Intention to Treat Analysis
16%
Peginterferon
16%
Peginterferon Alpha
50%
Polypeptide
16%
Procedures
16%
Professional Standard
16%
Recommended Drug Dose
16%
Regression Analysis
16%
Ribavirin
16%
Steatosis
16%
Sustained Virologic Response
66%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
33%
Albinterferon Alpha2b
50%
Alpha2a Interferon
50%
Alpha2b Interferon
16%
Chronic Hepatitis
16%
Chronic Hepatitis C
33%
Fibrosis
16%
Gamma Glutamyltransferase
16%
Hepacivirus
16%
Hepatitis C
33%
Hepatitis C Virus Genotype 2
33%
Hepatitis C Virus Genotype 3
16%
Human Albumin
16%
Human Interferon
16%
Peginterferon
16%
Peginterferon Alpha
50%
Polypeptide
16%
Ribavirin
16%
Steatosis
16%
Virus RNA
33%